New study from Sylvester Cancer, collaborators shows anti-cancer compound goes beyond current BTK inhibitors Peer-Reviewed Publication UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE “THIS NEW COMPOUND NOT ONLY INHIBITS THE CELLULAR MOLECULE BTK, BUT GOES FURTHER BY TAKING AIM AT THE TARGET AND DESTROYING IT,” SAID Justin Taylor, M.D., SYLVESTER HEMATOLOGIST-RESEARCHER AND THE STUDY’S SENIOR...
